...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >Hepatic miR-126 is a potential plasma biomarker for detection of hepatitis B virus infected hepatocellular carcinoma
【24h】

Hepatic miR-126 is a potential plasma biomarker for detection of hepatitis B virus infected hepatocellular carcinoma

机译：肝miR-126是用于检测乙型肝炎病毒感染肝细胞癌的潜在血浆生物标志物

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Controversies about the origin of circulating miRNAs have encouraged us to identify organ specific circulating miRNAs as disease biomarkers. To identify liver-specific miRNAs for hepatocellular carcinoma (HCC), global expression profiling of miRNAs in liver tissue of HBV-HCC and HBV-control with no or mild fibrosis was evaluated. A total of 40 differentially expressed miRNAs were identified in HCC. Among ten highly altered miRNAs, six miRNAs were successfully validated in tissues, whereas only two miRNAs, miR-126 and miR-142-3p showed increased expression in plasma of HBV-HCC compared to HBV-non-HCC patients. Subsequently, ROC curve analysis revealed that neither miR-126 nor miR-142-3p performed better than AFP in discriminating HCC from non-HCC while combination of each with AFP showed significantly higher efficiency rather than AFP alone (AUC: 0.922, 0.908 vs. 0.88; sensitivity: 0.84, 0.86 vs. 0.82 and specificity: 0.92, 0.94 vs. 0.86 respectively). Interestingly, triple combination of markers (miR-126 +/- miR-142-3p +/- AFP) showed no additive effect on efficiency (AUC: 0.925) over the dual combination. Again, the expression of only miR-126 was noticed significantly higher in HBV-HCC patients with low-AFP [< 250 ng/ml] compared to either non-HCC or liver cirrhosis (AUC: 0.77, 0.64, respectively). Furthermore, no alteration in expression of mir-126 in HCV-HCC or non-viral-HCC revealed that miR-126 + AFP might be specific to HBV-HCC. To understand the physiological role of these two miRNAs in hepato-carcinogenesis, target genes related to cancer pathways (APAF1, APC2, CDKN2A, IRS1, CRKL, LIFR, EGR2) were verified. Thus, combination of circulating miR-126 +/- AFP is a promising noninvasive diagnostic biomarker for HBV-HCC and may be useful in the management of HCC patients.
机译：关于循环miRNA的起源的争议鼓励我们识别器官特异性循环miRNA作为疾病生物标志物。为了鉴定肝细胞癌（HCC）的肝细胞特异性miRNA，评估HBV-HCC和NO或轻度纤维化的HBV-HCC和HBV对照中的MIRNA的全局表达分析。在HCC中鉴定了共40种差异表达的miRNA。在十个高度改变的miRNA中，在组织中成功验证了六种miRNA，而仅与HBV-非HCC患者相比，只有两个miRNA，miR-126和miR-142-3p显示出HBV-HCC血浆的表达增加。随后，ROC曲线分析显示，MIR-126和MIR-142-3P既比AFP在鉴别非HCC鉴别HCC时表现优于AFP，同时每种AFP的组合显示出明显更高的效率而不是单独的AFP（AUC：0.922,0.908。 0.88;灵敏度：0.84,0.86 vs.0.82和特异性：0.92,0.94与0.86分别）。有趣的是，标记的三倍组合（miR-126 +/- miR-142-3p +/- afp）显示了对双组合的效率（AUC：0.925）的添加剂效果。同样，与非HCC或肝硬化（AUC：0.77,0.64分别）相比，仅注意到患有低AFP [250 ng / mL]的HBV-HCC患者的MIR-126的表达明显高。此外，HCV-HCC或非病毒-HCC中MIR-126的表达没有改变，显示MIR-126 + AFP可能是HBV-HCC的特异性。为了了解这两种MiRNA在肝癌中的生理作用，验证了与癌症途径（APAF1，APC2，CDKN2A，IRS1，CRK1，LEVR，EGR2）相关的靶基因。因此，循环miR-​​126 +/- AFP的组合是HBV-HCC的有望的非侵入性诊断生物标志物，可用于HCC患者的管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号